Cargando…
Real-World Molecular Biomarker Testing Patterns and Results for Advanced Gastroesophageal Cancers in the United States
The decision to treat advanced gastroesophageal cancers (GECs) with targeted therapy and immunotherapy is based on key biomarker expression (human epidermal growth factor receptor 2 (HER2), programmed cell death-ligand 1 (PD-L1), microsatellite instability (MSI), and/or mismatch repair (MMR)). Real-...
Autores principales: | Mehta, Rutika, Liepa, Astra M., Zheng, Shen, Chatterjee, Anindya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955769/ https://www.ncbi.nlm.nih.gov/pubmed/36826106 http://dx.doi.org/10.3390/curroncol30020145 |
Ejemplares similares
-
Real-World Outcomes and Factors Associated With the Second-Line
Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal
Adenocarcinoma
por: Barzi, Afsaneh, et al.
Publicado: (2019) -
Reliability of Conclusions from Early Analyses of Real-World Data for Newly Approved Drugs in Advanced Gastric Cancer in the United States
por: Hess, Lisa M, et al.
Publicado: (2020) -
Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea
por: Carter, Gebra Cuyun, et al.
Publicado: (2017) -
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
por: Catenacci, Daniel V., et al.
Publicado: (2021) -
Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy
por: Mehta, Rutika, et al.
Publicado: (2018)